The latest list of publications from the NIHR Cambridge Biomedical Research Centre with a brief summary.
If you are publishing research which has had funding and / or support from the NIHR Cambridge Biomedical Research Centre, please complete this form.View publication
Publication: New England Journal of Medicine
Julia Ware, Janet M. Allen, Charlotte K. Boughton, Malgorzata E. Wilinska, Sara Hartnell, Ajay Thankamony, Carine de Beaufort, Ulrike Schierloh, Elke Fröhlich-Reiterer, Julia K. Mader, Thomas M. Kapellen, Birgit Rami-Merhar, Martin Tauschmann, Katrin Nagl, Sabine E. Hofer, Fiona M. Campbell, James Yong, Korey K. Hood, Julia Lawton, Stephane Roze, Judy Sibayan, Laura E. Bocchino, Craig Kollman, and Roman Hovorka
20 January 2021
In this multicenter, randomized, crossover trial, researchers recruited children 1 to 7 years of age with type 1 diabetes who were receiving insulin-pump therapy. Participants received treatment in two 16-week periods, in random order, in which the closed-loop system was compared with sensor-augmented pump therapy (control). Read the full press release.
Publication: BJGP Open
, , , , , , , , , , ,
14 December 2021
Compared with patients with other heart failure diagnoses in primary care, those with heart failure with preserved ejection fraction (HFpEF) are more likely to be women, obese, prefrail/frail, more functionally impaired and report more symptoms.View publication
Publication: npj Schizophrenia
Banerjee S, Liò P, Jones PB, Cardinal RN
8 December 2021
Machine learning (ML), one aspect of artificial intelligence (AI), involves computer algorithms that train themselves. They have been widely applied in the healthcare domain. However, many trained ML algorithms operate as ‘black boxes’, producing a prediction from input data without a clear explanation of their workings.
Researchers apply class-contrastive counterfactual reasoning to ML to demonstrate how specific changes in inputs lead to different predictions of mortality in people with severe mental illness (SMI).
Researchers produce predictions accompanied by visual and textual explanations as to how the prediction would have differed given specific changes to the input.View publication
Publication: Journal of the American Heart Association
Marinka Steur, Laura Johnson, Stephen J. Sharp, Fumiaki Imamura, Ivonne Sluijs, Timothy J. Key, Angela Wood, Rajiv Chowdhury, Marcela Guevara, Marianne U. Jakobsen, Ingegerd Johansson, Albert Koulman, Kim Overvad, Maria‐José Sánchez, Yvonne T. van der Schouw, Antonia Trichopoulou, Elisabete Weiderpass, Maria Wennberg, Ju‐Sheng Zheng, Heiner Boeing, Jolanda M. A. Boer, Marie‐Christine Boutron‐Ruault, Ulrika Ericson, Alicia K. Heath, Inge Huybrechts, Liher Imaz, Rudolf Kaaks, Vittorio Krogh, Tilman Kühn, Cecilie Kyrø, Giovanna Masala, Olle Melander, Conchi Moreno‐Iribas, Salvatore Panico, José R. Quirós, Miguel Rodríguez‐Barranco, Carlotta Sacerdote, Carmen Santiuste, Guri Skeie, Anne Tjønneland, Rosario Tumino, W. M. Monique Verschuren, Raul Zamora‐Ros, Christina C. Dahm, Aurora Perez‐Cornago, Matthias B. Schulze, Tammy Y. N. Tong, Elio Riboli, Nicholas J.Wareham, John Danesh, Adam S. Butterworth, and Nita G. Forouhi
7 December 2021
Once thought to be the best dietary advice for the prevention of heart attacks, reducing saturated fat in the diet is increasingly questioned as a strategy for improving heart health. This change, which is evident in the increasing popularity of low carbohydrate, not low fat diets, is happening for a variety of reasons.
Researchers conducted research across nine countries of Europe testing the link between different types of dietary fats and the future risk of developing heart disease. This study involved 10,529 people who developed heart disease over time and compared them with 16,730 people who did not develop heart disease, who were randomly selected from 385,747 European Prospective Investigation into Cancer (EPIC) study volunteers in the EPIC-CVD Study.View publication
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, Elena Provenzano, Helen A. Bardwell, Wenxin Ma, Wei Cope, Ali Dariush, Sarah-Jane Dawson, Jean E. Abraham, Janet Dunn, Louise Hiller, Jeremy Thomas, David A. Cameron, John M. S. Bartlett, Larry Hayward, Paul D. Pharoah, Florian Markowetz, Oscar M. Rueda, Helena M. Earl & Carlos Caldas
7 December 2021
Breast cancers are complex ecosystems of malignant cells and tumour microenvironment.
The composition of these tumour ecosystems and interactions within them contribute to cytotoxic therapy response. Researchers collected clinical, digital pathology, genomic and transcriptomic profiles of pre-treatment biopsies of breast tumours from 168 patients treated with chemotherapy +/- HER2-targeted therapy prior to surgery.View publication
EJ Needham, AL Ren, RJ Digby, JG Outtrim, DA Chatfield, AE Manktelow, VFJ Newcombe, R Doffinger, G Barcenas-Morales, C Fonseca, MJ Taussig, RM Burnstein, C Dunai, N Sithole, NJ Ashton, H Zetterberg, M Gisslen, A Edén, E Marklund, MJ Griffiths, J Cavanagh, G Breen, View ORCID ProfileSR Irani, A Elmer, N Kingston, JR Bradley, LS Taams, View ORCID ProfileBD Michael, ET Bullmore, KGC Smith, PA Lyons, AJC Coles, DK Menon, the Cambridge Neuro COVID Group, the NIHR COVID-19 BioResource, Cambridge NIHR Clinical Research Facility
5 December 2021
COVID-19 has been associated with many neurological complications including stroke, delirium and encephalitis. But it is unknown the full neurological injury Covid-19 has caused.
Researchers investigated the dynamics of, and relationship between, serum markers of brain injury and markers of dysregulated host response including measures of autoinflammation (proinflammatory cytokines) and autoimmunity.View publication
Publication: Lancet Regional Health Europe
Tessa Strain, Stephen J.Sharp, Andrew Spiers, Helen Price, Ciara Williams, Carol Fraser, Søren Brage, Katrien Wijndaele, Paul Kelly
29 November 2021
To limit the spread of COVID-19 in March 2020, the population of England was instructed to stay home, leaving only for essential shopping, health-care, work, or exercise. The impact on population activity behaviours is not clear. Researchers describe changes in duration and types of activity undertaken by adults ≥16 years in England between March and May 2016 and 2020, by socio-demographic strata. Restrictions introduced in Spring 2020 likely reduced physical activity levels in England. The magnitude of the declines were not uniform by demographic groups or by activity type, which future policies should consider.View publication
Publication: NEJM Evidence
Tian X. Zhao, Rouchelle S. Sriranjan, Zewen Kelvin Tuong, Yuning Lu, Andrew P. Sage, Meritxell Nus, Annette Hubsch, Fotini Kaloyirou, Evangelia Vamvaka, Joanna Helmy, Michalis Kostapanos, Navazh Jalaludeen, David Klatzmann, Alain Tedgui, James H.F. Rudd, Sarah J. Horton, Brian J.P. Huntly, Stephen P. Hoole, Simon P. Bond, Menna R. Clatworthy, Joseph Cheriyan, and Ziad Mallat,
22 November 2021
Atherosclerosis is a chronic inflammatory disease of the artery wall. Regulatory T cells (Tregs) limit inflammation and promote tissue healing. Low doses of interleukin (IL)-2 have the potential to increase Tregs, but its use is contraindicated for patients with ischemic heart disease.
In a randomized, double-blind, placebo-controlled, dose-escalation trial, researchers tested low-dose subcutaneous aldesleukin (recombinant IL-2), given once daily for 5 consecutive days.View publication
Publication: Nature Metabolism
Scott C. Ritchie, Samuel A. Lambert, Matthew Arnold, Shu Mei Teo, Sol Lim, Petar Scepanovic, Jonathan Marten, Sohail Zahid, Mark Chaffin, Yingying Liu, Gad Abraham, Willem H. Ouwehand, David J. Roberts, Nicholas A. Watkins, Brian G. Drew, Anna C. Calkin, Emanuele Di Angelantonio, Nicole Soranzo, Stephen Burgess, Michael Chapman, Sekar Kathiresan, Amit V. Khera, John Danesh, Adam S. Butterworth & Michael Inouye
8 November 2021
For the first time, scientists have used polygenic scoring to identify molecular drivers of cardiovascular disease and diabetes, which could be targeted to help prevent or treat some of these conditions.View publication
Publication: The Journal of Clinical Endocrinology & Metabolism
19 November 2021
Large size at birth is associated with complications in the mother and the baby. Alongside work in fetal growth restriction (FGR), researchers analysed their previously developed metabolite ratio in relation to large for gestational age (LGA) infants born at term.
They found that the metabolite ratio predictive of FGR was inversely associated with both LGA and birth weight z score as a continuous trait. These findings, obtained from the Pregnancy Outcome Prediction study, were externally validated in the Born in Bradford study.View publication
Publication: Journal of Nuclear Medicine
Maura Malpetti, Sanne S Kaalund, Kamen A Tsvetanov, Timothy Rittman, Mayen Briggs, Kieren Allinson, Luca Passamonti, Negin Holland, P Simon Jones, Tim D Fryer, Young T Hong, Antonina Kouli, Richard Bevan-Jones, Elijah Mak, George Savulich, Maria Grazia Spillantini, Franklin Aigbirhio, Caroline H Williams-Gray, John T O’Brien and James B Rowe
18 November 2021
Progressive brain diseases like dementia and Parkinson’s disease move through stages. A new system to stage the dementia-parkinsonian disease known as Progressive Supranuclear Palsy (PSP) has been developed in 2020. In 2021, researchers validated the new scheme at the Cambridge Brain Bank, looking at the disease severity at the end of life. Researchers wanted to know how the disease progresses and to stop it.
Researchers used a PET scan with a chemical “dye” called 18F-flortaucipi to measure PSP. Despite high hopes for PET using this dye to measure the burden of PSP, when the study began, the results of the study are clear – it does not support the staging of disease, either in lifetime or in terms of outcomes of the illness. 18F-Flortaucipir PET is successfully used in other diseases, like Alzheimer’s, but it cannot be used for PSP staging.View publication
Publication: Journal of Affective Disorders
Shanquan Chen, Athina R.Aruldass, Rudolf N.Cardinal
11 November 2021
In the first half of 2021, people in the USA who had had the COVID-19 vaccine were in general less likely to have anxiety and depressive symptoms (which might be a cause or a consequence). This effect varied with age, marital status, level of education, ethnicity, and income, but not gender.View publication